Study of FOLFIRI + Panitumumab Using Ultra-selection Technology of Patients With Stage IV Colorectal Cancer Refractory to Irinotecan Without Any Mutation on KRAS, PIK3Ca, BRAF and NRAS Genes Detected With Highly Sensitive Techniques
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.
Stage IV Colorectal Cancer
DRUG: panitumumab|DRUG: FOLFIRI
Objective response rate (TRO), 4 years
disease control rate (TCE), 4 years|duration of response (DR), 4 years|time to response(THR), 4 years|time to progression (THP), 4 years|time to treatment failure (THF), 4 years|duration of stable disease (DEE), 4 years|Progression free survival (SLP), 4 years|Overall survival (SG), 4 years|Adverse events, 4 years
Open label Phase II study of FOLFIRI + Panitumumab using ultra-selection technology with next generation high sensitivity genotyping of patients with stage IV colorectal cancer refractory to irinotecan without any mutation on KRAS, PIK3Ca, BRAF and NRAS genes detected with highly sensitive techniques.